MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592501 | Name: Pronetalol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pronetalol is a non-selective beta blocker. Pronetalol is a beta-adrenergic antagonist and an inhibitor of Sox2 expression. Pronetalol fails to potentiate quinidine in some antiarrhythmic tests.

Chemical Structure

Pronetalol
Pronetalol
CAS#54-80-8

Theoretical Analysis

MedKoo Cat#: 592501

Name: Pronetalol

CAS#: 54-80-8

Chemical Formula: C15H19NO

Exact Mass: 229.1467

Molecular Weight: 229.32

Elemental Analysis: C, 78.56; H, 8.35; N, 6.11; O, 6.98

Price and Availability

Size Price Availability Quantity
5mg USD 220.00
10mg USD 355.00
25mg USD 590.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Pronetalol
IUPAC/Chemical Name
2-Isopropylamino-1-(naphth-2-yl)ethanol
InChi Key
HRSANNODOVBCST-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H19NO/c1-11(2)16-10-15(17)14-8-7-12-5-3-4-6-13(12)9-14/h3-9,11,15-17H,10H2,1-2H3
SMILES Code
CC(NCC(O)C1=CC=C2C=CC=CC2=C1)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 229.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang D, Qiao X, Yao J, Zhang L, Wu X, Ma J, Cai X, Bostrom KI, Yao Y. Pronethalol Reduces Sox2 (SRY [Sex-Determining Region Y]-Box 2) to Ameliorate Vascular Calcification. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):931-933. doi: 10.1161/ATVBAHA.120.315571. Epub 2020 Dec 10. PMID: 33297753; PMCID: PMC8105260. 2: Qiao X, Zhang D, Zhang L, Yao J, Wu X, Cai X, Boström KI, Yao Y. Pronethalol decreases RBPJκ to reduce Sox2 in cerebral arteriovenous malformation. Vasc Med. 2020 Dec;25(6):569-571. doi: 10.1177/1358863X20942833. Epub 2020 Aug 24. PMID: 32833597; PMCID: PMC8034816. 3: Aronson JK, Green AR. Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. Br J Clin Pharmacol. 2020 Nov;86(11):2114-2122. doi: 10.1111/bcp.14327. Epub 2020 May 13. PMID: 32358800; PMCID: PMC7576625. 4: Yao J, Wu X, Zhang D, Wang L, Zhang L, Reynolds EX, Hernandez C, Boström KI, Yao Y. Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. J Clin Invest. 2019 Jun 24;129(8):3121-3133. doi: 10.1172/JCI125965. PMID: 31232700; PMCID: PMC6668698. 5: Wen YQ, Hertzberg R, Gonzalez I, Moberg C. Minor enantiomer recycling: application to enantioselective syntheses of beta blockers. Chemistry. 2014 Mar 24;20(13):3806-12. doi: 10.1002/chem.201303890. Epub 2014 Feb 26. PMID: 24574310. 6: Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and propranolol. 1965. Br J Pharmacol. 2010 Jul;160 Suppl 1(Suppl 1):S28-42; discussion S26-7. doi: 10.1111/j.1476-5381.2010.00850.x. PMID: 20590649; PMCID: PMC2947413. 7: Hollenberg NK. The role of beta-blockers as a cornerstone of cardiovascular therapy. Am J Hypertens. 2005 Dec;18(12 Pt 2):165S-168S. doi: 10.1016/j.amjhyper.2005.09.010. PMID: 16373194. 8: Lodén H, Hedeland Y, Hedeland M, Bondesson U, Pettersson C. Development of a chiral non-aqueous capillary electrophoretic system using the partial filling technique with UV and mass spectrometric detection. J Chromatogr A. 2003 Jan 31;986(1):143-52. doi: 10.1016/s0021-9673(02)01866-6. PMID: 12585332. 9: Kim HK, Hong JH, Park MS, Kang JS, Lee MH. Determination of propranolol concentration in small volume of rat plasma by HPLC with fluorometric detection. Biomed Chromatogr. 2001 Dec;15(8):539-45. doi: 10.1002/bmc.110. PMID: 11748690. 10: Carlsson Y, Hedeland M, Bondesson U, Pettersson C. Non-aqueous capillary electrophoretic separation of enantiomeric amines with (-)-2,3:4,6-di-O- isopropylidene-2-keto-L-gulonic acid as chiral counter ion. J Chromatogr A. 2001 Jul 13;922(1-2):303-11. doi: 10.1016/s0021-9673(01)00925-6. PMID: 11486876. 11: Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and propranolol. 1965. Br J Pharmacol. 1997 Feb;120(4 Suppl):285-99; discussion 283-4. doi: 10.1111/j.1476-5381.1997.tb06809.x. PMID: 9142411; PMCID: PMC3224304. 12: Rekhi GS, Jambhekar SS, Souney PF, Williams DA. A fluorimetric liquid chromatographic method for the determination of propranolol in human serum/plasma. J Pharm Biomed Anal. 1995 Nov;13(12):1499-505. doi: 10.1016/0731-7085(95)01575-2. PMID: 8788135. 13: Vilà JI, Calpena AC, Obach R, Domenech J. Gastric, intestinal and colonic absorption of a series of beta-blockers in the rat. Int J Clin Pharmacol Ther Toxicol. 1992 Aug;30(8):280-6. PMID: 1356102. 14: Spahn-Langguth H, Podkowik B, Stahl E, Martin E, Mutschler E. Improved enantiospecific RP-HPLC assays for propranolol in plasma and urine with pronethalol as internal standard. J Anal Toxicol. 1991 Nov-Dec;15(6):327-31. doi: 10.1093/jat/15.6.327. PMID: 1685758. 15: Spahn-Langguth H, Podkowik B, Stahl E, Martin E, Mutschler E. Improved enantiospecific RP-HPLC assays for propranolol in plasma and urine with pronethalol as internal standard. J Anal Toxicol. 1991 Jul-Aug;15(4):209-13. doi: 10.1093/jat/15.4.209. PMID: 1682529. 16: Prichard BN. Beta-blockage therapy and cardiovascular disease. Past, present, and future. Postgrad Med. 1988 Feb 29;Spec No:8-18. PMID: 2894664. 17: Dynarowicz I, Mortensen A, Watkowski T. Udział receptorów adrenergicznych w regulacji przepływu krwi przez narzad rozrodczy świni w przebiegu cyklu płciowego [The role of adrenergic receptors in the regulation of blood flow in the reproductive organs of swine during the estrous cycle]. Pol Arch Weter. 1988;28(3-4):115-27. Polish. PMID: 2856079. 18: Lawson JW. Inhibition of quinidine-propranolol elevation of the ventricular fibrillation threshold by bilateral stellectomy+vagotomy in the anesthetized dog. Arch Int Pharmacodyn Ther. 1986 Mar;280(1):74-83. PMID: 3718083. 19: Cooper DP, Styles J, Bradbrook C, Charlesworth JD, Chu YH, O'Connor PJ, Margison GP. Methylated purines formed in DNA by dimethylnitrosamine in rats previously exposed to hepatotoxic and hepatocarcinogenic regimes: effects on the repair of O6-methylguanine. Chem Biol Interact. 1985 May;53(3):283-301. doi: 10.1016/s0009-2797(85)80105-8. PMID: 2860979. 20: Dashputra PG, Patki VP, Hemnani TJ. Antiepileptic action of beta-adrenergic blocking drugs: pronethalol and propranolol. Mater Med Pol. 1985 Apr- Jun;17(2):88-92. PMID: 2867256.

View History

CP-195543

CP-195543